vs
Ingevity Corp（NGVT）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是Ingevity Corp的1.2倍（$219.9M vs $185.4M），Orthofix Medical Inc.净利率更高（-1.0% vs -45.6%，领先44.6%），Ingevity Corp同比增速更快（36.7% vs 2.0%），Ingevity Corp自由现金流更多（$73.5M vs $16.8M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -26.2%）
Ingevity Corp是一家全球特种化学品与先进材料生产商，主营高性能碳材料、路面养护解决方案及特种化工产品，服务汽车排放控制、工业净化、道路基建、农业投入品等核心市场，业务覆盖北美、欧洲及亚太地区。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
NGVT vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.2倍
$185.4M
营收增速更快
NGVT
高出34.8%
2.0%
净利率更高
OFIX
高出44.6%
-45.6%
自由现金流更多
NGVT
多$56.7M
$16.8M
两年增速更快
OFIX
近两年复合增速
-26.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $185.4M | $219.9M |
| 净利润 | $-84.6M | $-2.2M |
| 毛利率 | 41.2% | 71.1% |
| 营业利润率 | -47.7% | 0.2% |
| 净利率 | -45.6% | -1.0% |
| 营收同比 | 36.7% | 2.0% |
| 净利润同比 | -609.6% | 92.4% |
| 每股收益（稀释后） | $-2.33 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NGVTOFIX
| Q4 25 | $185.4M | $219.9M | ||
| Q3 25 | $333.1M | $205.6M | ||
| Q2 25 | $365.1M | $203.1M | ||
| Q1 25 | $284.0M | $193.6M | ||
| Q4 24 | $135.6M | $215.7M | ||
| Q3 24 | $333.8M | $196.6M | ||
| Q2 24 | $390.6M | $198.6M | ||
| Q1 24 | $340.1M | $188.6M |
净利润NGVTOFIX
| Q4 25 | $-84.6M | $-2.2M | ||
| Q3 25 | $43.5M | $-22.8M | ||
| Q2 25 | $-146.5M | $-14.1M | ||
| Q1 25 | $20.5M | $-53.1M | ||
| Q4 24 | $16.6M | $-29.1M | ||
| Q3 24 | $-107.2M | $-27.4M | ||
| Q2 24 | $-283.7M | $-33.4M | ||
| Q1 24 | $-56.0M | $-36.0M |
毛利率NGVTOFIX
| Q4 25 | 41.2% | 71.1% | ||
| Q3 25 | 40.2% | 72.2% | ||
| Q2 25 | 37.8% | 68.7% | ||
| Q1 25 | 39.9% | 62.8% | ||
| Q4 24 | 81.3% | 69.0% | ||
| Q3 24 | 39.4% | 68.7% | ||
| Q2 24 | 31.5% | 67.8% | ||
| Q1 24 | 29.3% | 67.5% |
营业利润率NGVTOFIX
| Q4 25 | -47.7% | 0.2% | ||
| Q3 25 | 18.7% | -8.3% | ||
| Q2 25 | -39.1% | -7.9% | ||
| Q1 25 | 9.4% | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | 33.0% | -9.6% | ||
| Q2 24 | 25.9% | -12.5% | ||
| Q1 24 | 22.6% | -15.6% |
净利率NGVTOFIX
| Q4 25 | -45.6% | -1.0% | ||
| Q3 25 | 13.1% | -11.1% | ||
| Q2 25 | -40.1% | -6.9% | ||
| Q1 25 | 7.2% | -27.4% | ||
| Q4 24 | 12.2% | -13.5% | ||
| Q3 24 | -32.1% | -13.9% | ||
| Q2 24 | -72.6% | -16.8% | ||
| Q1 24 | -16.5% | -19.1% |
每股收益（稀释后）NGVTOFIX
| Q4 25 | $-2.33 | $-0.05 | ||
| Q3 25 | $1.18 | $-0.57 | ||
| Q2 25 | $-4.02 | $-0.36 | ||
| Q1 25 | $0.56 | $-1.35 | ||
| Q4 24 | $0.44 | $-0.76 | ||
| Q3 24 | $-2.94 | $-0.71 | ||
| Q2 24 | $-7.81 | $-0.88 | ||
| Q1 24 | $-1.54 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $78.1M | $82.0M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $29.7M | $450.0M |
| 总资产 | $1.7B | $850.6M |
| 负债/权益比越低杠杆越低 | 39.10× | — |
8季度趋势，按日历期对齐
现金及短期投资NGVTOFIX
| Q4 25 | $78.1M | $82.0M | ||
| Q3 25 | $83.4M | $62.9M | ||
| Q2 25 | $76.9M | $65.6M | ||
| Q1 25 | $71.5M | $58.0M | ||
| Q4 24 | $68.0M | $83.2M | ||
| Q3 24 | $135.5M | $30.1M | ||
| Q2 24 | $107.4M | $26.4M | ||
| Q1 24 | $88.5M | $27.0M |
总债务NGVTOFIX
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $157.2M | ||
| Q2 25 | $1.2B | $157.0M | ||
| Q1 25 | $1.3B | $156.9M | ||
| Q4 24 | $1.3B | $157.0M | ||
| Q3 24 | $1.4B | $118.5M | ||
| Q2 24 | $1.4B | $118.0M | ||
| Q1 24 | $1.4B | $118.2M |
股东权益NGVTOFIX
| Q4 25 | $29.7M | $450.0M | ||
| Q3 25 | $138.1M | $442.5M | ||
| Q2 25 | $120.7M | $458.3M | ||
| Q1 25 | $234.6M | $458.3M | ||
| Q4 24 | $195.2M | $503.1M | ||
| Q3 24 | $214.5M | $525.9M | ||
| Q2 24 | $284.8M | $546.0M | ||
| Q1 24 | $568.2M | $570.3M |
总资产NGVTOFIX
| Q4 25 | $1.7B | $850.6M | ||
| Q3 25 | $1.8B | $832.6M | ||
| Q2 25 | $1.9B | $837.2M | ||
| Q1 25 | $2.1B | $823.1M | ||
| Q4 24 | $2.0B | $893.3M | ||
| Q3 24 | $2.2B | $867.9M | ||
| Q2 24 | $2.3B | $882.0M | ||
| Q1 24 | $2.6B | $906.0M |
负债/权益比NGVTOFIX
| Q4 25 | 39.10× | — | ||
| Q3 25 | 8.39× | 0.36× | ||
| Q2 25 | 10.24× | 0.34× | ||
| Q1 25 | 5.68× | 0.34× | ||
| Q4 24 | 6.86× | 0.31× | ||
| Q3 24 | 6.52× | 0.23× | ||
| Q2 24 | 4.92× | 0.22× | ||
| Q1 24 | 2.48× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $97.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $73.5M | $16.8M |
| 自由现金流率自由现金流/营收 | 39.6% | 7.6% |
| 资本支出强度资本支出/营收 | 12.7% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $273.5M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流NGVTOFIX
| Q4 25 | $97.1M | $27.7M | ||
| Q3 25 | $129.7M | $12.4M | ||
| Q2 25 | $79.0M | $11.6M | ||
| Q1 25 | $25.4M | $-18.4M | ||
| Q4 24 | $64.5M | $23.7M | ||
| Q3 24 | $46.5M | $11.7M | ||
| Q2 24 | $29.7M | $9.0M | ||
| Q1 24 | $-12.1M | $-18.6M |
自由现金流NGVTOFIX
| Q4 25 | $73.5M | $16.8M | ||
| Q3 25 | $117.8M | $2.5M | ||
| Q2 25 | $66.8M | $4.5M | ||
| Q1 25 | $15.4M | $-25.1M | ||
| Q4 24 | $39.6M | $15.2M | ||
| Q3 24 | $28.5M | $6.3M | ||
| Q2 24 | $11.6M | $-360.0K | ||
| Q1 24 | $-28.7M | $-29.1M |
自由现金流率NGVTOFIX
| Q4 25 | 39.6% | 7.6% | ||
| Q3 25 | 35.4% | 1.2% | ||
| Q2 25 | 18.3% | 2.2% | ||
| Q1 25 | 5.4% | -13.0% | ||
| Q4 24 | 29.2% | 7.0% | ||
| Q3 24 | 8.5% | 3.2% | ||
| Q2 24 | 3.0% | -0.2% | ||
| Q1 24 | -8.4% | -15.4% |
资本支出强度NGVTOFIX
| Q4 25 | 12.7% | 4.9% | ||
| Q3 25 | 3.6% | 4.8% | ||
| Q2 25 | 3.3% | 3.5% | ||
| Q1 25 | 3.5% | 3.5% | ||
| Q4 24 | 18.4% | 4.0% | ||
| Q3 24 | 5.4% | 2.7% | ||
| Q2 24 | 4.6% | 4.7% | ||
| Q1 24 | 4.9% | 5.6% |
现金转化率NGVTOFIX
| Q4 25 | — | — | ||
| Q3 25 | 2.98× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.24× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NGVT
| Performance Materials | $151.2M | 82% |
| Advanced Polymer Technologies Segment | $36.5M | 20% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
